Trials / Not Yet Recruiting
Not Yet RecruitingNCT07283692
Neoadjuvant Serplulimab Plus Weekly Paclitaxel and Carboplatin in TNBC (Neo-SERPENT)
NEOadjuvant SERplulimab Plus Weekly PaclitaxEl and carboplatiN in Triple-negative Breast Cancer: a Prospective, Single-arm, Multicenter, Phase 2 Clinical Trial
- Status
- Not Yet Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 46 (estimated)
- Sponsor
- RenJi Hospital · Academic / Other
- Sex
- Female
- Age
- 18 Years – 70 Years
- Healthy volunteers
- Not accepted
Summary
This is an prospective, open label, multicenter study to evaluate the efficacy and safety of neoadjuvant serplulimab plus weekly paclitaxel and carboplatin in patients with triple-negative breast cancer.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Serplulimab | 1.5mg/kg qw, start from C1D15 |
| DRUG | Paclitaxel | 80mg/m\^2 qw |
| DRUG | Carboplatin | AUC=1.5, D1, 8, 15, every 28 days |
Timeline
- Start date
- 2026-02-01
- Primary completion
- 2026-12-01
- Completion
- 2031-09-01
- First posted
- 2025-12-16
- Last updated
- 2026-02-03
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT07283692. Inclusion in this directory is not an endorsement.